Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
02:27:05 EDT Fri 19 Apr 2024
Enter Symbol
or Name
USA
CA



News for U:IMVT from 2023-04-20 to 2024-04-19 - 16 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-03-12 07:30U:IMVTNews ReleaseImmunovant Awarded U.S. Patent for IMVT-1402
2024-02-12 07:00U:IMVTNews ReleaseImmunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023
2024-01-03 08:00U:IMVTNews ReleaseImmunovant to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-20 16:30U:IMVTNews ReleaseImmunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves ¢ € ™ Disease
2023-12-20 16:30U:IMVTNews ReleaseRoivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves ¢ € ™ Disease
2023-11-28 07:00U:IMVTNews ReleaseRoivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
2023-11-28 07:00U:IMVTNews ReleaseImmunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
2023-11-13 08:00U:IMVTNews ReleaseImmunovant to Present at Upcoming Investor Conferences
2023-11-09 07:00U:IMVTNews ReleaseImmunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended September 30, 2023
2023-10-02 16:52U:IMVTNews ReleaseImmunovant Announces Closing of Upsized Common Stock Financing and Full Exercise of Underwriters ¢ € ™ Option to Purchase Additional Shares
2023-09-27 23:42U:IMVTNews ReleaseImmunovant Announces Pricing of $450 Million Common Stock Financing
2023-09-26 17:00U:IMVTNews ReleaseImmunovant Announces Proposed Offering of $300 Million of Common Stock
2023-09-26 06:00U:IMVTNews ReleaseImmunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results
2023-09-25 23:02U:IMVTNews ReleaseImmunovant to Host Conference Call and Webcast to Report Initial IMVT-1402 Phase 1 Results on September 26, 2023
2023-08-10 07:00U:IMVTNews ReleaseImmunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2023
2023-05-22 07:00U:IMVTNews ReleaseImmunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023